Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments
Background. The aims of this study were to assess patients’ preferences to wait or start systemic treatment and understand how patients would make tradeoffs between certain severe adverse events (AEs) and additional months of progression-free survival (PFS). Materials and Methods. Adults in France,...
Main Authors: | Ateesha F. Mohamed, Juan Marcos González, Angelyn Fairchild |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | Journal of Thyroid Research |
Online Access: | http://dx.doi.org/10.1155/2015/438235 |
Similar Items
-
REFRACTORY OF WELL-DIFFERENTIATED THYROID CANCER TO THE TREATMENT WITH RADIOACTIVE IODINE
by: P. O. Rumyantsev
Published: (2015-04-01) -
Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer
by: Francis Worden
Published: (2014-11-01) -
LENVATINIB IN TREATMENT OF RADIOACTIVE IODINE-REFRACTORY WELL-DIFFERENTIATED THYROID CARCINOMA
by: I. S. Romanov, et al.
Published: (2017-06-01) -
Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy
by: Jierui Liu, et al.
Published: (2019-09-01) -
Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation
by: Angelica Schmidt, et al.
Published: (2017-02-01)